Table 1 Patients’ baseline clinical characteristics
From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
Characteristics | n (%) |
|---|---|
Median age (rang)(years) | 53 (36–67) |
FIGO stage | |
IIIA | 1 (2.44%) |
IIIB | 3 (7.32%) |
IIIC | 33 (80.48%) |
IV | 4 (9.76%) |
ECOG PS | |
0 | 31 (75.61%) |
1 | 6 (14.63%) |
2 | 4 (9.76%) |
Histology type | |
High-grade serous carcinoma | 29 (70.73%) |
Low-grade serous carcinoma | 9 (21.95%) |
Mucinous carcinoma | 2 (4.88%) |
Endometrioid carcinoma | 1 (2.44%) |
Debulking surgery | |
Optimal | 14 (34.15%) |
Suboptimal | 27 (65.85%) |
Biochemical recurrence | |
Yes | 19 (46.34%) |
No | 22 (53.66%) |
Previous chemotherapy lines | |
1–2 | 29 (70.73%) |
3–5 | 12 (29.27%) |
Treatment regimen | |
Combined chemotherapy | 13 (31.71%) |
Monotherapy | 28 (68.29%) |